Literature DB >> 25943306

Physiological, pathological, and structural implications of non-enzymatic protein-protein interactions of the multifunctional human transglutaminase 2.

Kajal Kanchan1, Mónika Fuxreiter, László Fésüs.   

Abstract

Transglutaminase 2 (TG2) is a ubiquitously expressed member of an enzyme family catalyzing Ca(2+)-dependent transamidation of proteins. It is a multifunctional protein having several well-defined enzymatic (GTP binding and hydrolysis, protein disulfide isomerase, and protein kinase activities) and non-enzymatic (multiple interactions in protein scaffolds) functions. Unlike its enzymatic interactions, the significance of TG2's non-enzymatic regulation of its activities has recently gained importance. In this review, we summarize all the partners that directly interact with TG2 in a non-enzymatic manner and analyze how these interactions could modulate the crosslinking activity and cellular functions of TG2 in different cell compartments. We have found that TG2 mostly acts as a scaffold to bridge various proteins, leading to different functional outcomes. We have also studied how specific structural features, such as intrinsically disordered regions and embedded short linear motifs contribute to multifunctionality of TG2. Conformational diversity of intrinsically disordered regions enables them to interact with multiple partners, which can result in different biological outcomes. Indeed, ID regions in TG2 were identified in functionally relevant locations, indicating that they could facilitate conformational transitions towards the catalytically competent form. We reason that these structural features contribute to modulating the physiological and pathological functions of TG2 and could provide a new direction for detecting unique regulatory partners. Additionally, we have assembled all known anti-TG2 antibodies and have discussed their significance as a toolbox for identifying and confirming novel TG2 regulatory functions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25943306     DOI: 10.1007/s00018-015-1909-z

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  182 in total

1.  Sequence and structure-based prediction of eukaryotic protein phosphorylation sites.

Authors:  N Blom; S Gammeltoft; S Brunak
Journal:  J Mol Biol       Date:  1999-12-17       Impact factor: 5.469

2.  Roles of calcium ions in the activation and activity of the transglutaminase 3 enzyme.

Authors:  Bijan Ahvazi; Karen M Boeshans; William Idler; Ulrich Baxa; Peter M Steinert
Journal:  J Biol Chem       Date:  2003-04-04       Impact factor: 5.157

Review 3.  Transglutaminases in wound healing and inflammation.

Authors:  E A M Verderio; T S Johnson; M Griffin
Journal:  Prog Exp Tumor Res       Date:  2005

4.  The monoclonal antibody 6B9 recognizes CD44 and not cell surface transglutaminase 2.

Authors:  J Stamnaes; B Fleckenstein; F Lund-Johansen; L M Sollid
Journal:  Scand J Immunol       Date:  2008-09-18       Impact factor: 3.487

5.  Identification of a factor that links apoptotic cells to phagocytes.

Authors:  Rikinari Hanayama; Masato Tanaka; Keiko Miwa; Azusa Shinohara; Akihiro Iwamatsu; Shigekazu Nagata
Journal:  Nature       Date:  2002-05-09       Impact factor: 49.962

6.  Phospholipase C-delta1 and oxytocin receptor signalling: evidence of its role as an effector.

Authors:  E S Park; J H Won; K J Han; P G Suh; S H Ryu; H S Lee; H Y Yun; N S Kwon; K J Baek
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

7.  Identification of the eukaryotic initiation factor 5A as a retinoic acid-stimulated cellular binding partner for tissue transglutaminase II.

Authors:  U S Singh; Q Li; R Cerione
Journal:  J Biol Chem       Date:  1998-01-23       Impact factor: 5.157

8.  Interaction site of GTP binding Gh (transglutaminase II) with phospholipase C.

Authors:  K C Hwang; C D Gray; N Sivasubramanian; M J Im
Journal:  J Biol Chem       Date:  1995-11-10       Impact factor: 5.157

9.  Prediction and functional analysis of native disorder in proteins from the three kingdoms of life.

Authors:  J J Ward; J S Sodhi; L J McGuffin; B F Buxton; D T Jones
Journal:  J Mol Biol       Date:  2004-03-26       Impact factor: 5.469

10.  Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-terminal epitopes not displayed on the surface of cells.

Authors:  Rasmus Iversen; Roberto Di Niro; Jorunn Stamnaes; Knut E A Lundin; Patrick C Wilson; Ludvig M Sollid
Journal:  J Immunol       Date:  2013-05-20       Impact factor: 5.422

View more
  20 in total

Review 1.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

2.  Transglutaminases factor XIII-A and TG2 regulate resorption, adipogenesis and plasma fibronectin homeostasis in bone and bone marrow.

Authors:  Aisha Mousa; Cui Cui; Aimei Song; Vamsee D Myneni; Huifang Sun; Jin Jin Li; Monzur Murshed; Gerry Melino; Mari T Kaartinen
Journal:  Cell Death Differ       Date:  2017-04-07       Impact factor: 15.828

3.  Regulation of allergic lung inflammation by endothelial cell transglutaminase 2.

Authors:  Frank Soveg; Hiam Abdala-Valencia; Jackson Campbell; Luisa Morales-Nebreda; Gökhan M Mutlu; Joan M Cook-Mills
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-07-24       Impact factor: 5.464

4.  Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.

Authors:  Abdullah Akbar; Nicole M R McNeil; Marie R Albert; Viviane Ta; Gautam Adhikary; Karine Bourgeois; Richard L Eckert; Jeffrey W Keillor
Journal:  J Med Chem       Date:  2017-09-14       Impact factor: 7.446

5.  Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload.

Authors:  Arti V Shinde; Ya Su; Brad A Palanski; Kana Fujikura; Mario J Garcia; Nikolaos G Frangogiannis
Journal:  J Mol Cell Cardiol       Date:  2018-03-02       Impact factor: 5.000

Review 6.  Ion channel regulation by β-secretase BACE1 - enzymatic and non-enzymatic effects beyond Alzheimer's disease.

Authors:  Sandra Lehnert; Stephanie Hartmann; Sabine Hessler; Helmuth Adelsberger; Tobias Huth; Christian Alzheimer
Journal:  Channels (Austin)       Date:  2016-06-02       Impact factor: 2.581

7.  Biochemical Characterization of Medaka (Oryzias latipes) Transglutaminases, OlTGK1 and OlTGK2, as Orthologues of Human Keratinocyte-Type Transglutaminase.

Authors:  Ayaka Kikuta; Eri Furukawa; Ryota Ogawa; Natsuki Suganuma; Mai Saitoh; Toshiyuki Nishimaki; Takafumi Katsumura; Hiroki Oota; Tadafumi Kawamoto; Hideki Tatsukawa; Hisashi Hashimoto; Kiyotaka Hitomi
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

Review 8.  Transglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and death.

Authors:  H Tatsukawa; Y Furutani; K Hitomi; S Kojima
Journal:  Cell Death Dis       Date:  2016-06-02       Impact factor: 8.469

9.  An initial assessment of the involvement of transglutaminase2 in eosinophilic bronchitis using a disease model developed in C57BL/6 mice.

Authors:  Lan Chen; Shuyan Liu; Linzhuo Xiao; Kanyao Chen; Juanjuan Tang; Chuqin Huang; Wei Luo; Dominique Ferrandon; Kefang Lai; Zi Li
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379

Review 10.  Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review.

Authors:  Tiina Rauhavirta; Minna Hietikko; Teea Salmi; Katri Lindfors
Journal:  Clin Rev Allergy Immunol       Date:  2019-08       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.